Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR

NCT07651007 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
29
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Wang Xin